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Abstract  
ADAMTS-2 is a metalloproteinase that plays a key role in the processing of fibrillar procollagen precursors into 
mature collagen molecules by excising the amino-propeptide. We demonstrate that recombinant ADAMTS-2 is 
also able to reduce proliferation of endothelial cells, and to induce their retraction and detachment from the 
substrate resulting in apoptosis. Dephosphorylation of Erk1/2 and MLC largely precedes the ADAMTS-2 
induced morphological alterations. In 3-D culture models, ADAMTS-2 strongly reduced branching of capillary-
like structures formed by endothelial cells and their long-term maintenance and inhibited vessels formation in 
embryoid bodies (EB). Growth and vascularization of tumors formed in nude mice by HEK 293-EBNA cells 
expressing ADAMTS-2 were drastically reduced. A similar anti-tumoral activity was observed when using cells 
expressing recombinant deleted forms of ADAMTS-2, including catalytically inactive enzyme. Nucleolin, a 
nuclear protein also found to be associated with the cell membrane, was identified as a potential receptor 
mediating the antiangiogenic properties of ADAMTS-2. 
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Abbreviations 
EB                             Embryoid body 
EBM                             Endothelial basal medium 
ES cell                          Embryonic stem cell 
HEK 293-EBNA cell     Human embryonic kidney 293- Epstein Barr nuclear antigen cell  
HMEC                          Human microvascular endothelial cell  
HMVEC                        Human dermal microvascular endothelial cell  
HSF                              Human skin fibroblasts 
HSMC                          Human smooth muscle cell 
HSPG:                           Heparan sulfate proteoglycan 
HUVEC                        Human umbilical vein endothelial cell  
MLC                             Myosin light chain 
mTS2                            Catalytically inactive ADAMTS-2 
PAK                             p21 Activated kinase 
PECAM                        Platelet endothelial cell adhesion molecule: CD31  
ROCK                           Rho kinase 
TSR1                            Thrombospondin repeat type 1 
TS-2                             ADAMTS-2 
wtTS2                           Wild-type ADAMTS-2 
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Introduction 
Angiogenesis, the process by which neovasculature is formed from existing blood vessels, is essential in normal 
development and plays a critical role in several pathological conditions such as cancer, rheumatoid arthritis, and 
diabetic retinopathy [1, 2]. Vascularization of tumors is critical for their growth beyond a few mm [3] and for 
cancer cells to escape to distant sites through hematogenous spreading and metastasis. Accordingly, it was 
proposed that inhibition of angiogenesis could be an efficient anti-cancer therapy that further targets genetically 
stable cells [3]. In this context, identification and characterization of endogenous inhibitors of blood vessel 
formation is of critical importance. It is anticipated that they should be less prone to induce side-effects and 
resistance to treatment than synthetic inhibitors. 
In recent years, a number of endogenous inhibitors of angiogenesis have been identified, many of them deriving 
from extracellular matrix (ECM) components. Some of these inhibitors are effective either as native full-length 
proteins or as proteolytic fragments [2]. This is the case for thrombospondins (TSP) 1 and 2, for which the 
mechanisms leading to inhibition of angiogenesis have been extensively studied and characterized [4]. Short 
sequences present in the N-terminal domain, especially in the thrombospondin type 1 repeats (TSR1), are 
released by ADAMTS-1 [5] and inhibit angiogenesis by interacting with the CD36 scavenger receptor [6-8]. 
Another class of inhibitors are active only as fragments derived from larger matrix macromolecules such as type 
XVIII collagen (endostatin), type XV collagen (restin), the !1, !2, and !3 chains of type IV collagen (arresten, 
canstatin, and tumstatin) and perlecan (endorepellin) [1]. Signaling from these molecules most probably involves 
binding or interference with specific integrins [1, 9]. A third class of angiogenesis regulators comprises secreted 
enzymes, most of which are proangiogenic by facilitating endothelial cells migration through degradation of 
matrix macromolecules and promoting the release of pro-angiogenic cytokines and growth factors immobilized 
in the ECM. However, some of these enzymes can also, in defined circumstances, inhibit angiogenesis. 
Angiostatin, a potent inhibitor of angiogenesis, is a proteolytic fragment of plasminogen [10, 11] and matrix 
metalloproteinases can generate anti-angiogenic fragments by proteolytic processing of some ECM proteins (see 
above, and [12]). As another example, two metalloproteinases of the ADAMTS family, ADAMTS-1 and -8, 
were also reported to strongly inhibit angiogenesis [13, 14]. The most striking characteristic of the ADAMTS 
enzymes is the presence, in addition to the metalloproteinase and disintegrin domains, of at least one domain 
highly similar to the TSR1 found in thrombospondins 1 and 2. Studies investigating the anti-angiogenic 
properties of ADAMTS-1 suggest that several domains are implicated, including a TSR1 domain [15]. The 
catalytic activity of ADAMTS-1 is also implicated in its anti-angiogenic function since it alters in vitro 
endothelial cells adhesion and migration [15] and is essential for inhibiting angiogenesis in vivo in xenograft 
assays [16]. It may also act by interacting with VEGF [13]. 
Among the other members of the ADAMTS family, ADAMTS-2 is one of the best characterized [17, 18]. It 
contains four TSR1 domains and a RGD sequence in a Cys-rich domain that could potentially bind to integrins. 
Its primary function is to cleave the amino propeptides of type I, II, III and V procollagens [19-21], explaining 
its previous name "aminoprocollagen peptidase". Mutations in the ADAMTS-2 gene cause dermatosparaxis in 
human (dermatosparactic type of Ehlers-Danlos syndrome, also known as Ehlers-Danlos syndrome type VIIC) 
and other mammals [20, 22]. This inherited connective tissue disorder arises as a result of accumulation of 
incorrectly processed aminoprocollagen and its cardinal feature is an extreme skin fragility. Adamts2 knockout 
mice have been created [23]. In addition to skin fragility, male infertility was related to altered maturation of 
spermatogonia, suggesting that ADAMTS-2 may have functions other than procollagen processing. An 
alternative splicing mechanism and complex maturation processes of the secreted enzyme have been described, 
generating various polypeptides that are not implicated in procollagen processing [19]. 
In this work, the anti-angiogenic properties of ADAMTS-2 in vitro and in vivo are demonstrated and initial 
characterizations of the mechanisms involved in its biological activity are reported. 
Materials and methods 
Cell cultures 
Human umbilical vein endothelial cells (HUVEC) were isolated as previously described [24]. Human dermal 
microvascular endothelial cells (HMVEC) were purchased from LONZA (LONZA, Verviers, Belgium). 
HUVEC and HMVEC were seeded on gelatin-coated culture dishes and grown in endothelial basal medium 
(EBM) supplemented with SingleQuot Kit (LONZA). Human microvascular endothelial cells (HMEC) [25],   
human primary skin fibroblasts (HSF) [26], and human smooth muscle cells (HSMC) [27] were grown in 
Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Grand Island, NY) supplemented with 10% FBS 
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(LONZA). Heparinase III and chondroitinase were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, 
USA). 
Production and purification of wild recombinant ADAMTS-2 and controls 
Recombinant bovine ADAMTS-2 was produced in HEK 293-EBNA cells as previously described [19]. 
Although recombinant ADAMTS-2 was highly purified [19], co-purification of any product secreted by HEK 
293-EBNA cells that could potentially hamper the analysis of experimental data could not be totally excluded. In 
order to take into account this possibility, control samples were produced from HEK 293-EBNA cells transfected 
with the empty vector using the same purification procedures as described for recombinant ADAMTS-2. The 
electrophoretic patterns of purified control medium and of purified ADAMTS-2 was determined on a SDS-
PAGE stained with SYPRO® Ruby Protein Gel Stain (BioRad, Hercules, CA) as described by the manufacturer. 
For any experimental condition, the effect of ADAMTS-2 was always compared to the effect observed with a 
similar volume of the purified control medium. 
Cell proliferation assay 
Cell proliferation assays were performed by two different methods. In the first one, cells were seeded (HMEC: 
2.5 " 104 cells/cm2; HUVEC, HMVEC, HSF: 1 " 104 cells/cm2) in 24-multiwell plates (Cellstar, Greiner Bioone 
Frickenhausen, Germany) coated with gelatin in EBM supplemented with 0.5% FBS. After 3 h, the medium was 
discarded and cells were incubated in EBM containing 0.5% FBS and ADAMTS-2 or the control sample. After 
24 h, the culture medium was replaced by the same medium containing 0.4 #M [3H]-thymidine (6.7 Ci/mmol; 
PerkinElmer Life Sciences, Boston, MA, USA) and 0.6 #M cold thymidine (Sigma-Aldrich). After 20 h, cells 
were washed twice with DMEM and sonicated in 500 #l PBS. Incorporation of thymidine was determined by 
measuring the TCA (cold, 5% final) insoluble radioactivity collected by filtration on glass microfiber filters 
(GF/A, Whatmann, Maidstone, United Kingdom). 
For the second method, HEK 293-EBNA cells were seeded (1.6 " 104 cells/cm2) in 6-multiwell plates (Cellstar) 
in DMEM supplemented with 10% FBS. At days 0, 1, 2, 3, 4 and 5, the DNA was measured by a fluorimetric 
technique using bis-benzimide [28]. 
Cell morphology and immunocytochemical staining 
In a first set of experiments, cells were seeded on gelatin-coated 24-multiwell plates in EBM supplemented with 
0.5% FBS. In a second set of experiments, cells were seeded in non-supplemented EBM on gelatin-coated or 
fibronectin-coated (0.25 #g/cm2) 4-wells LabTek© chambered coverglasses (Nalge Nunc International, IL, USA) 
for immunocytochemical staining or on gelatin-coated or fibronectin-coated 24-multiwell plates for observation 
by phase contrast microscopy. For all experiments, the medium was discarded after 3 h of attachment and 
spreading, and replaced by fresh medium containing, when indicated, 5 #g/ml of ADAMTS-2 or control sample. 
After 16 h, cells were fixed with 3% formaldehyde in PBS for 30 min and permeabilized for 3 min in PBS 
containing 0.1% Triton® X-100 (Merck, Darmstadt, Germany). Vinculin staining was performed using a 
monoclonal antibody against vinculin (dilution 1:1,000 for 1 h; V9131; Sigma-Aldrich) followed by Alexa Fluor 
546 rabbit anti-mouse IgG (2 #g/ml final concentration, for 1 h; Molecular Probes, Eugene, OR, USA), F-actin 
was stained with 100 ng/ml FITC-Phalloidin (Sigma-Aldrich) in PBS for 20 min. Nuclei were stained with 0.2 
#g/ml bis-benzimide (Calbiochem, La Jolla, CA, USA) in PBS. After mounting using Aqua Poly/Mount 
(Polysciences, INC, Warrington, PA, USA), cells were observed with Zeiss Axiovert 25 microscope equipped 
with an Axiocam Zeiss camera and the KS 400 Kontron image analysis software. 
Time-lapse video imaging 
HUVEC and HSF were seeded (3.3 " 104 cells/cm2) in Glass Bottom Culture Dishes No. 1.5 coated with 
collagen (MatTek Co, Ashland, MA) in EBM supplemented with 0.5% FBS. After 5 h, the medium was replaced 
by fresh medium containing 5 #g/ml of ADAMTS-2 or control sample. Time-lapse videomicroscopy was 
performed using a Leica TS-2 confocal microscope (Leica, Wetzlar, Germany). Images were recorded every 5 
min for 20 h. All time-lapse imaging was performed under 5% CO2 and 37°C in a controlled stage incubator. 
Western-blot analysis 
HUVEC were seeded (3.3 " 104 cells/cm2) on gelatin-coated 24-multiwell plates in serum-free EBM. After 3 h, 
ADAMTS-2 was added in the medium to obtain a final concentration of 5 #g/ml. The same volume of the 
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control sample was used in parallel cultures. After increasing the time of incubation, the cells were lyzed in 
Laemmli denaturation buffer. Proteins were separated by SDS-PAGE and transferred onto a PVDF membrane 
(NEN Life Science Products, Boston, MA, USA). After blocking with non-fat milk, membranes were incubated 
with primary antibody, washed, and then incubated with horseradish peroxidase-conjugated secondary antibodies 
(Dako, Carpinteria, CA, USA) at room temperature for 1 h. The blots were revealed by using an enhanced 
chemiluminescence assay (ECL, Amersham Biosciences Ltd, England) and X-ray film exposure. The antibody 
reagents used were: anti-phospho-p38 MAP Kinase (Biosource P0601, Camarillo, CA, USA); anti-phospho-
p42/44 MAP Kinase (M-8159) and anti-MAP Kinase (M-5670) (Sigma-Aldrich); anti-phospho-myosin light 
chain (MLC) (Thr18/ Ser 19; clone 12896) and anti-MLC (clone 15370) (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA); anti-phospho-FAK (Tyr 397) (Upstate, Lake Placid, NY, USA); anti-FAK (BD Biosciences 
Pharmingen, San Jose, CA, USA); anti-phospho-p21 activated kinase (PAK) was a kind gift of M. E. Greenberg 
(Children's Hospital, Harvard Medical School, Boston, MA); anti-nucleolin (clone H250, Santa Cruz 
Biotechnology). 
Apoptosis analysis 
HUVEC were seeded (3.3 " 104 cells/cm2) on gelatin-coated 12-multiwell plates (Cellstar) in serum-free EBM or 
in EBM supplemented with 0.5% FBS. After 3 h, medium was replaced by EBM containing 5 #g/ml ADAMTS-
2 and supplemented or not with 0.5% FBS. After 30 min, 120 min, 240 min, or 18 h of incubation, medium was 
collected and cells were trypsinized, pooled with the medium, and centrifuged to collect any floating cells. Cells 
were then suspended in Annexin binding buffer (Annexin V-FITC Apoptosis Detection kit, Sigma) at the 
concentration of 1 " 105 cells/ml and incubated for 10 min with Annexin V-FITC (270 ng/ml) and propidium 
iodide (1.1 #g/ml). Cell analysis was performed using FACS (BD FACS Canto, BD Biosciences) and statistical 
significance was determined using one-way ANOVA test. 
ADAMTS-2 immunostaining 
HMEC were seeded in DMEM medium supplemented by 10% FBS. After 16 h, the medium was discarded and 
cells were incubated for 6 h at 8°C in serum-free medium containing, when indicated, 0.5 or 2 #g/ml of 
ADAMTS-2 or control sample, supplemented or not with heparin (10 #g/ml; Sigma-Aldrich). For other 
experiments, cells were first pretreated with 6 mU/ml heparinase III (4 h at 37°C) or 0.1 U/ml chondroitinase (4 
h at 37°C), or with 20 mM sodium chlorate with or without 10 mM sodium sulfate (16 h at 37°C) before 
incubation with ADAMTS-2 or control sample. For all these experiments, cells after incubation with ADAMTS-
2 were washed with DMEM and fixed with 3% paraformaldehyde at room temperature for 30 min. The washed 
cell layer was incubated sequentially in PBS containing 3% bovine serum albumin for 30 min, mouse 
monoclonal antibodies against ADAMTS-2 for 1 h (mAb23; [19]), Alexa Fluor 546 rabbit anti-mouse IgG for 1 
h (Molecular Probes, A-11060), and, when indicated, rabbit polyclonal anti-human nucleolin (H250, Santa Cruz 
Biotechnology) and Alexa Fluor 488 goat anti-rabbit IgG for 1 h (Molecular Probes, A-11034). Nuclei staining 
was performed using DAPI at 1 #g/ml for 20 min (Roche, 236276). After mounting in Aqua Poly/Mount 
(Polysciences) cells were observed with a Zeiss Axiovert 25 inverted microscope. 
Isolation and identification of ADAMTS-2-binding proteins 
Antibody against ADAMTS-2 (mab23, [19]) was immobilized on a Affi-gel® HZ resin (Bio-Rad) as described 
by the manufacturer. Purified recombinant ADAMTS-2 was then incubated with resin in order to allow 
immobilization of ADAMTS-2 by binding with antibody against ADAMTS-2. Resin without ADAMTS-2 was 
used as control. Resins were poured in a column and equilibrated in 50 mM Tris HCl, pH 7.5, 2 mM CaCl2, 0.1 
M NaCl. HMEC were scraped from the dish and incubated 30 min on ice in extraction buffer (0.2% Triton X-
100, pH 7.0, 100 mM N-ethylmaleimide, 0.2 mM phenylmethanesulfonyl fluoride, 5 mM benzamide). Cells 
were then centrifuged 25 min at 20,000 " g. Supernatant was collected, diluted in one volume of equilibration 
buffer containing NaCl to obtain 0.1% Triton X-100 and 0.1 M NaCl final concentration and loaded on column 
with immobilized ADAMTS-2 or on control resin. After extensive washing in the equilibration buffer, elution 
was performed (50 mM Tris HCl, pH 7.5, 2 mM CaCl2, 0.5 M NaCl). Eluted fractions were dialyzed against 200 
mM ammonium acetate and 0.01% sodium dodecyl sulfate, lyophilized, and resuspended in Laemmli buffer. 
Proteins were then separated by SDS-PAGE and stained by Coomassie Blue. The differential pattern between 
the control and ADAMTS-2 affinity chromatography allowed to identify potential proteins of interest. Their 
identification was performed after extraction from the polyacrylamide gel by micro high-performance liquid 
chromatography-electrospray ionization-trap (#HPLC-ESI-Trap; Esquire-Bruker Daltonics, Billerica, MA). 
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Capillary-like structures formation assay 
The capillary-like structures assay was performed as previously described [29]. When indicated, 2 or 5 #g/ml 
ADAMTS-2 or control sample was added to the collagen solution and to the medium. Changes in cell 
morphology and formation of capillary-like structures were evaluated by phase-contrast microscopy. The mean 
length of the structures and the number of branching per mm were determined. 
Embryoid bodies 
Undifferentiated embryonic stem CGR8 (ES) cells were aggregated by culture on bacteriological dishes during 4 
days in a 20-#l hanging drop of DMEM supplemented with 10% FBS, 0.1 mM non-essential amino acids, 0.1 
mM !-mercaptoethanol, and 10 ng/ml of VEGF to induce cell clustering and differentiation into endothelial cells 
[30]. The aggregates were seeded on gelatin-coated glass coverslips in the same medium supplemented with 
recombinant ADAMTS-2 or control sample. Media were renewed every 48 h for 8 days.                                         
For immunohistochemistry, the embryoid bodies were fixed in methanol and incubated with rat anti-mouse 
CD31 antibodies (Pharmingen, San Diego, CA), biotin-conjugated anti-rat IgG, and streptavidin/FITC. Nuclei 
were stained with 0.2 #g/ml bisbenzimide (Calbiochem) in PBS. The surface of the embryoid body and the total 
vessel length by representative microscope field was determined by manual measurement on enlarged pictures. 
Growth of HEK 293-EBNA tumors in nude mice 
HEK 293-EBNA cells transfected with ADAMTS-2 cDNA (wild-type, mutated, or truncated) or empty vector 
[19] were resuspended at 4°C in growth factor-depleted Matrigel (BD Biosciences) solubilized in serum-free 
DMEM to a final concentration of 2 " 107 cells/ml. Cell suspension (100 #l) was injected subcutaneously into 
the flanks of mice, each mouse being injected with HEK 293-EBNA cells transfected with ADAMTS-2 on the 
left side and with HEK 293-EBNA cells transfected with empty vector on the right side. Tumor size was 
monitored every 3-4 days by measuring two perpendicular diameters and the height using a caliper. Mice were 
killed according to the animal ethical policy of the University of Liège when the apparent size of the tumor 
exceeded 1,500-2,500 mm. Tumors were weighed and then fixed in buffered 3% paraformaldehyde solution for 
routine histology or embedded in optimal cutting temperature compound (Tissue TeK, Miles Laboratories, 
Naperville, Ill) and frozen for cryostat sectioning. Cryostat sections (5 #m thick) were fixed first in acetone at -
20°C and then in methanol at 4°C before incubation with rat monoclonal antibody against mouse platelet 
endothelial cell adhesion molecule (PECAM) (Pharmingen). Slides were then incubated with rabbit anti-rat 
antibody coupled with biotin (E468, Dako) followed by incubation with streptavidin/HRP complex (P0397, 
Dako). Slides were finally counterstained with hematoxylin and mounted with Eukitt medium for microscope 
observation. 
Results 
Recombinant ADAMTS-2 was produced and purified from medium conditioned by HEK 293-EBNA cells 
transfected with an ADAMTS-2 expression vector. A control sample was produced using HEK 293-EBNA cells 
transfected with an empty vector and submitted to a purification process identical to that used for recombinant 
ADAMTS-2. Both preparations were used in parallel in the following experiments. 
Effect of ADAMTS-2 on cell proliferation 
Recombinant ADAMTS-2 added at increasing concentrations (0.8-5 #g/ml, corresponding to 7-44 nM) 
significantly reduced the H-thymidine uptake by HUVEC after 2 days of contact as compared to the cells treated 
with the control sample taken as 100% (Fig. 1a, black bars). A similar inhibition of the proliferation was also 
observed when using HMVEC in the same conditions (Fig. 1a, dark grey bars). No significant effect was found 
for fibroblasts (Fig. 1a, clear grey bars). The anti-angiogenic effect of ADAMTS-2 was as effective when 
endothelial cell proliferation was stimulated by VEGF and/or FGF-2 (not shown). 
ADAMTS-2 alters endothelial cells morphology and cytoskeleton 
After 3 h of seeding on gelatin coat, the three types of endothelial cells (HUVEC, HVMEC, and HMEC) had 
already well spread (not shown) and their morphology did not change during an additional 16 h incubation in 
control medium (Fig. 1Ba, b, c). In the presence of ADAMTS-2, subtle changes in endothelial cell morphology 
were already observed after 15-20 min and accentuated with time (Fig. 1Bd, e, f). Many cells appeared more 
refringent, retracted and rounded, and clustered into aggregates with many cell protruding processes resembling 
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filipodia and podosomes. Similar results were obtained for bovine aortic endothelial cells (BAEC) (not shown) 
or for HUVEC and HMEC seeded on gelatin or fibronectin (Fig. S1) or on collagen (not shown). In contrast, 
ADAMTS-2 did not alter the morphology of human skin fibroblasts (HSF) or smooth-muscle cells (HSMC) 
(Fig. 1B, compare g, h to i, j). 
In order to better visualize the dynamics of the process, time-lapse video microscopy was performed (available 
as supplemental material). In control conditions, cells remained well-spread, actively formed membrane ruffles 
and did not migrate at long distance. In the presence of ADAMTS-2, endothelial cells progressively lost their 
adherence to the substrate, migrated farther and faster, established cell-cell contacts, assembled into clusters and 
finally died after 1 day. The same experiment performed with fibroblasts did not show any significant 
morphological or dynamic changes (not shown). 
The organization of the cytoskeleton of HUVEC cultured on fibronectin was visualized by staining fibrillar actin 
(Fig. 2a) and focal adhesions (Fig. 2b). In control conditions, HUVEC displayed actin stress fibers anchored into 
focal adhesions as seen in the merged pictures (Fig. 2S). Treatment by ADAMTS-2 for 16 h (Fig. 2c, d) resulted 
in a disruption of the network of actin stress fibers and dissolution of many focal adhesions, leaving streaks of 
cortical actin along the protruding processes. Similar results were obtained with HUVEC cultured on gelatin in 
the presence of ADAMTS-2 (not shown). 
 
Fig. 1 Recombinant ADAMTS-2 inhibits endothelial cells proliferation and alters their morphology. a The 
proliferation rate of HUVEC (black bars), HMVEC (dark grey bars), or human skin fibroblasts (light grey bars) 
was measured by 3H-thymidine incorporation in cultures (n = 6) supplemented with 0.5% FBS and increasing 
concentrations (0.8-5 "g/ml) of ADAMTS-2, or of the same volume of the control preparation (0 "g/ml). The 
results are expressed in percentage of incorporation as compared to the respective controls. The results are 
representative of three separate experiments for HMVEC and fibroblasts and ten separate experiments for 
HUVEC. (***p < 0.001). B Cells were seeded on gelatin coat for 3 h in EBM supplemented with 0.5% FBS and 
cultured for 16 h in control medium (a, b, c, g, h) or in the presence of ADAMTS-2 at 5 "g/ml (d, e, f, i, j). Bar 
100 "m 
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Fig. 2 ADAMTS-2 causes disassembly of actin stress fibers and focal adhesions in HUVEC. HUVEC were 
seeded on fibronectin coat for 3 h in serum-free EBM and cultured for 16 h in control medium (a, b) or in 
medium supplemented with ADAMTS-2 at 5 "g/ml (c, d). Cells were fixed, permeabilized with 0.1% Triton X-
100, and stained to visualize actin stress fibers (FITC-Phalloidin; a, c) and focal adhesions (anti-vinculin mAb 
and TRITC-conjugated secondary antibody; b, d). Focal adhesion appears as small red spots at the extention of 




ADAMTS-2 destabilizes the capillary-like structures formed in vitro by HUVEC 
Confluent monolayers of HUVEC cultured on a thin collagen gel displayed a cobblestone-like morphology (not   
shown   and   [29]). Upon addition of a covering collagen gel, cells migrated and formed, within 16 h, capillary-
like structures. Addition of ADAMTS-2 only mildly affected the initial steps of this process (Fig. 4, compare e to 
a, c). This is in agreement with morphology data showing that addition of ADAMTS-2 does not affect cell 
migration and cell-cell interactions. However, while the capillary-like structures remained stable for at least 4-5 
days in the cultures either containing medium supplemented with FBS alone (Fig. 4Ab, b') or further 
supplemented with the control preparation (Fig. 4Ad, d'), the organization of the tube-like structures in the 
cultures supplemented with ADAMTS-2 was strongly altered after 36 h (Fig. 4Af, f'), with short segments of 
disassembled vessels and many isolated cells being observed. The quantification of the mean length and number 
of branchings of the capillary-like structures in the various culture conditions  (Fig. 4b, c) further confirmed 
visual observation. 
ADAMTS-2 induces apoptosis in HUVEC 
HUVEC were stained with annexin V-FITC and propidium iodide (PI) and analyzed by FACS in order to 
evaluate the induction of apoptosis by ADAMTS-2 in the various culture conditions. Due to their limited 
lifespan in vitro and their high sensitivity towards culture conditions, especially in reduced serum concentration, 
some apoptotic HUVEC were detected in control conditions (Fig. 3a). Staurosporine, used as positive control, 
strongly increased apoptosis already after 4 h (Fig. 3b, c, grey bars). In the presence of ADAMTS-2, apoptosis 
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tended to raise already after 4 h and was strongly increased after 20 h as compared to the respective control 
conditions (Fig. 3b, c, black bars), confirming the time lapse videomicroscopy data (supplemental material). 
 
Fig. 3 ADAMTS-2 induces endothelial cell apoptosis. Three hours after seeding without or with 0.5% FBS, 
culture medium was supplemented with control preparation, ADAMTS-2 (5 "g/ml) or staurosporine (1 "g/ml) as 
a positive pro-apoptotic control. Cells were then collected after increasing times in culture, stained with annexin 
V-FITC and PI, and analyzed by FACS. a An example of cell distribution is provided (20 h of incubation without 
FBS in control conditions or in the presence of ADAMTS-2). Total number of cells stained by annexin V-FITC 
only (early apoptotic) and double stained by annexin V-FITC and PI (late apoptotic) was used to monitor 
induction of apoptosis by ADAMTS-2 in a time-course experiment in the absence (b) or in the presence of (c) 
FBS. The results are expressed as the ratio between the apoptosis induced by ADAMTS-2 (black bars) or 
Staurosporine (grey bars) and their respective control (treated/control), b n = 3; c n = 4; ***p < 0.001; **p < 
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Fig. 4 Effect of ADAMTS-2 on capillary-like structures formed by HUVEC. A HUVEC were cultured between 
two collagen gels in medium containing 10% FBS alone (a, b), or supplemented with the control preparation (c, 
d) or with ADAMTS-2 at 5 "g/ml (e, f). Pictures were taken after 16 h (a, c, e) or 36 h (b, d, f). Bars 100 "m. 
Mean length of all visible structures (B) and number of branching of the capillary-like structures (C) were 
calculated (n = 30 pictures) for cultures in medium alone (open bars) or supplemented with ADAMTS-2 at 2 or 5 
"g/ml (black bars) or with the same volume of control sample (grey bars). The results are representative of at 
least three separate experiments (***p < 0.001) 
 
 
ADAMTS-2 inhibits vessels formation in embryoid bodies 
The properties of ADAMTS-2 were further evaluated in vitro on the differentiation of ES cells into vascular 
structures in EB induced by VEGF. The vessels were visualized by detection of CD31, in whole-mount 
immunofluorescence microscopy, as a peripheral ring of elongated and branched tubular structures (Fig. 5A). As 
compared to controls, addition of ADAMTS-2 resulted in a significant reduction of the vessel density (Fig. 5b) 
without modifying the overall growth of EB as illustrated by DAPI staining of the nuclei (Fig. 5Aa, c). 
Furthermore, beating heart in EB was not altered by ADAMTS-2 (not shown) as additional evidence that the 
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differentiation and function of other cell types were not impaired. 
Fig. 5 ADAMTS-2 inhibits the formation of vascular structures in embryoid bodies. A Embryoid bodies were 
formed by culturing ES cells in medium containing VEGF alone (not shown) or further supplemented with the 
control preparation (a, b) or with ADAMTS-2 at 0.2 "g/ml (c, d). Nuclei were stained with DAPI (a, c) and 
forming vessels with an anti-CD31 antibody (b, d). Vessels formed by differentiated endothelial cells appear as 
elongated and branched green structures. Bar 1 mm. B Mean length of vessels in EB cultured in medium 
containing VEGF alone (open bars, n = 3), or supplemented with control sample (light grey bars, n = 20), or 
with ADAMTS-2 at 0.2 "g/ml (black bars, n = 18) were calculated (***p < 0.001) 
 
 
ADAMTS-2 binds to endothelial cells surface 
Live endothelial cells in monolayer cultures were incubated with ADAMTS-2 or the control preparation at 8°C 
in order to prevent internalization. After fixation and labeling of the non-permeabilized cells with an anti-
ADAMTS-2 monoclonal antibody, an intense and punctated staining of endothelial cell surface was observed in 
cultures supplemented with ADAMTS-2 (Fig. 6, compare a and b). Fibroblasts were also positive (Fig. 6c). In 
the presence of heparin, the labeling was strongly reduced but not completely abolished (Fig. 6d). Similar effects 
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were observed when cells were pre-treated with sodium chlorate in order to prevent sulfation process (Fig. 6e). 
This inhibition was completely reversed by adding sodium sulfate together with chlorate to restore sulfation (Fig. 
6f). These results suggested the involvement of binding motifs containing heparan sulfate. Similarly, a 
heparinase III pretreatment strongly reduced, but did not completely abolish, ADAMTS-2 binding at the cell 
surface (Fig. 6g), while digestion with chondroitinase had no effect (Fig. 6h). In another set of experiments, cells 
initially preincubated with ADAMTS-2 at 8°C were brought to 37°C and immunostained at increasing time after 
re-warming. In  these conditions, an active internalization process was visualized already after 15 min and was 
almost complete after 2 h (not shown). 
Although the participation of heparan sulphate proteoglycans (HSPG) in ADAMTS-2 immobilization at the cell 
surface was firmly established, heparinase III pretreatment did not significantly modify the effect of ADAMTS-2 
on endothelial cell morphology and proliferation (not shown), suggesting the existence of a signaling cell surface 
receptor. For its identification, extracts of endothelial cell membranes were submitted to column chromatography 
on either immobilized ADAMTS-2 as a bait or non-coupled resin as control. Besides a few unspecific proteins 
eluting from both columns, nucleolin was identified by peptide mass fingerprinting in two fractions specifically 
eluted from the ADAMTS-2 coupled resin. These data were further confirmed by Western blotting, which 
identified four different processed forms of nucleolin (Fig. S3). 
Co-localization studies were performed in order to evaluate the interaction between ADAMTS-2 and nucleolin in 
a cellular context. Non-permeabilized endothelial cells were successively pretreated with heparinase III, 
incubated at 8°C with ADAMTS-2 and fixed before double immunostaining of ADAMTS-2 and nucleolin (Fig. 
7). The pattern of surface nucleolin was punctated and spread over the entire cell surface. The nuclei remained 
negative, confirming the absence of cell permeabilization. Staining of ADAMTS-2 also revealed a punctated 
pattern. These positive spots were less numerous than spots positive for nucleolin but always colocalized with 
nucleolin positive structures as illustrated by the yellow to orange colors on the merge pictures. Most of these 
double-positive spots were localized at the cell edge. 
ADAMTS-2 intracellular signaling 
The phosphorylation status of various signaling proteins was assessed after addition of ADAMTS-2 to serum-
starved spread HUVEC. A slight repression of FAK phosphorylation was induced by addition of ADAMTS-2, as 
compared to control (Fig. 8a). A progressive reduction of the total amount of FAK with time was also observed 
in some experiments but was not further investigated since it was not regulated by the presence of ADAMTS-2. 
Myosin light chain, an operational protein of the actin stress-fibers, was investigated. A decreased level of 
phosphorylation was already apparent after 10 min of incubation with ADAMTS-2 and persisted for at least 2 h 
(Fig. 8b). By using Y27632, a Rho kinase (ROCK) inhibitor, the level of phosphorylated MLC was also strongly 
reduced (not shown). However, this reduction did not result in alteration of cell morphology, and did not prevent 
or increase the effect of ADAMTS-2. The level of phosphorylated Erk1/2 decreased with time in control 
conditions while a much faster reduction of phosphorylation was induced by ADAMTS-2 in HUVEC (Fig. 8c) 
whereas it was not modified, or even slightly increased, in fibroblasts (Fig. 8d). Phosphorylation of two other 
signaling proteins, PAK and p38, was not modified by ADAMTS-2 (not shown). 
Targeted deletion of ADAMTS-2 in mice results in an increased angiogenic response to ocular LASER injury 
Wild-type (WT) and ADAMTS-2 deficient (ADAMTS-2-/-) mice were used in a model of choroidal 
neovascularization following LASER burn injury. Fourteen days after LASER impact, the delay for maximal 
neovascularization [31], the mice were perfused with dextranfluorescein and the vascular density was evaluated 
using confocal microscopy and digital image capture. Neovascularization was observed only at the sites initially 
injured by the LASER and was significantly and reproducibly higher in ADAMTS-2 as compared to WT mice 
(Fig. S4). Evaluation, by quantitative RT-PCR, of the level of various mRNA coding for proteins involved in 
healing and angiogenesis as listed in Table SI (supplemental material) was also performed. No difference was 
observed between WT and ADAMTS-2-/- for any mRNA and at any time point after LASER burn (not shown). 
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Fig. 6 Binding of ADAMTS-2 at the cell surface. HMEC (a, b, d-h) and fibroblasts (c) were incubated for 6 h at 
8°C in serum-free medium supplemented with control preparation (a) or ADAMTS-2 at 2 "g/ml (b-h) in the 
absence (a-c, e-h) or presence of 10 "g/ml heparin (d) and then immunostained for the presence of ADAMTS-2 
immobilized at the cell surface. For a second set of experiments, HMEC were first pretreated for 16 h with 20 
mM sodium chlorate alone (e) or with sodium chlorate in the presence of 10 mM sodium sulfate (f) or for 4 h 
with 6 mU/ml heparinase III (g) or 0.1 U/ml chondroitinase (h). After pre-treatment, medium was changed and 
cells were cultured for 6 h at 8°C in the presence of ADAMTS-2 before staining as described above. Bar 50 "m 
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Fig. 7 ADAMTS-2 and nucleolin co-localization at the cell-surface HMEC were pretreated for 4 h with 6 mU/ml 
heparinase III, incubated for 6 h at 8°C in serum-free medium supplemented with ADAMTS-2 at 0.5 "g/ml, and 
stained to visualize ADAMTS-2 (red) and nucleolin (green) at the cell surface. A merged picture of the two 
stainings shows co-localization of the two proteins (arrows). Bar 10 "m 
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Fig. 8 Effect of ADAMTS-2 on the phosphorylation of Erk1/2, MLC and FAK. HUVEC (a, b, c) or fibroblasts (d) 
were seeded in serum-free medium and allowed to spread for 3 h at 37°C. ADAMTS-2 (TS-2) and control 
preparation (CTRL) were then added for various times. Cell lysates were analyzed by Western blotting using 
antibodies for phosphorylated FAK (p-FAK) and total FAK (a), phosphorylated MLC (p-MLC) and total MLC 
(b) and phosphorylated Erk1/2 (p-Erk1/2) and total Erk1/2 (c, d). Scanning density of the bands obtained in at 
least three independent experiments was used to calculate the relative level of p-FAK versus total FAK (n = 6) 
(a'), p-MLC versus total MLC (n = 3) (b') and p-Erk1/ 2 versus total Erk1/2 (n = 8) (c', d') in the various 
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ADAMTS-2 inhibits tumor growth 
HEK 293-EBNA cells stably transfected with the control vector   or   expressing   ADAMTS-2   were   mixed   
with Matrigel and subcutaneously injected in the flanks of six nude mice, control cells in one side, and 
ADAMTS-2 expressing cells in the contralateral side. The six plugs containing control cells generated growing 
tumors (Fig. 9a). By contrast, tumoral development was not observed in the ADAMTS-2 expressing cells, only 
one out of the six ADAMTS-2 plugs starting to slightly grow at day 30. After killing, dissected tumors were 
weighed, clearly demonstrating a dramatic difference in the mean tumoral mass (Fig. 9b). While control tumors 
appeared reddish with a well-developed peritumoral vascular network (Fig. 9c), ADAMTS-2 expressing tumors 
were whiter and little vascularized. A Western-blot analysis failed to reveal significant accumulation of 
ADAMTS-2 at the time of the animal killing, suggesting that most of the HEK 293-EBNA cells expressing 
ADAMTS-2 either died or stopped to produce ADAMTS-2. This was confirmed by immunohistochemistry 
analysis showing that only a few cells at the periphery of tumors was still producing ADAMTS-2 (not shown). A 
second independent experiment (n = 4) performed in similar conditions gave identical results, further 
demonstrating the efficiency and the reproducibility of the inhibition (Fig. 12a). Histological examination 
revealed the presence of large aggregates of HEK 293-EBNA cells in control tumors (Fig. 10a), containing both 
capillaries and larger vessels (Fig. 10b). In the small tumors formed by cells expressing ADAMTS-2, necrotic 
areas and collapsed vessels were noted (Fig. 10a, b). 
The catalytic activity of ADAMTS-2 is dispensable for antiangiogenic activity 
Three additional constructs coding for catalytically inactive ADAMTS-2 or for ADAMTS-2 lacking either the 
central or the C-terminal domains were created and used for stable transfection of HEK 293-EBNA cells. The 
proliferation rate of these cell lines in vitro was similar and close to that of the control cells or cells expressing 
the wild-type enzyme (Fig. 12e). These cells were also used for the production of recombinant enzymes. Out of 
these three ADAMTS-2 mutants, only the catalytically inactive form could be purified using the protocol 
developed for the wild-type enzyme. The electrophoretic pattern of these two recombinant forms was strongly 
different (Fig. 11a) since the wild-type form was essentially found as a fully processed molecule from which 
both the prodomain and the PNP domain are cleaved while the catalytic mutant still retained the PNP domain as 
previously described [19]. Their relative effects were compared in various in vitro models. The catalytic mutant 
was able to modify both the morphology (Fig. 11b) and the proliferation rate (Fig. 11e) of endothelial cells 
although less drastically than observed for the wild-type enzyme. Both types of enzymes bound also with a 
similar efficiency to the surface of endothelial cells (Fig. 11d). 
The cell lines expressing the wild-type and the three mutant forms  of ADAMTS-2 were evaluated for their 
ability to generate tumors (Fig. 12a-d). While the injection of control cells resulted in the formation of rapidly 
growing tumors, none of the three mutant cell lines induce significant tumoral growth. This shows that the three 
mutated forms of ADAMTS-2, including the catalytically inactive form, were as efficient as the wild-type 
enzyme for preventing tumor growth. 
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Fig. 9 ADAMTS-2 inhibits growth of HEK 293-EBNA tumors in nude mice. HEK 293-EBNA cells stably 
transfected with empty vector or expressing ADAMTS-2 were mixed with Matrigel and subcutaneously injected 
into each flank of the mice, one with control cells (control) and the other with ADAMTS-2 (TS-2) expressing 
cells (n = 6). a Growth of plugs containing control cells (plain black lines) or ADAMTS-2 expressing cells 
(dotted grey lines) was evaluated by measuring the tumor's volume every 3-4 days. Mice were killed when the 
apparent volume of one of the bilateral tumors reached 1,500 mm3, b Mean values of tumor mass for control 
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Fig. 10 Immunohistological examination of control and ADAMTS-2-expressing tumors. a Paraffin sections of 
tumors formed by control or by ADAMTS-2-expressing cells were stained with hematoxylin and eosin stain 
(H&E). Necrotic cells were visible only in ADAMTS-2 tumors (arrows). b Cryostat sections of tumors were 
stained by an anti-CD31 antibody for visualizing blood vessels (in brown). Bar 100 "m 
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Fig. 11 The catalytic activity of ADAMTS-2 is dispensable for antiangiogenic activity. a Sypro Ruby staining of 
purified control preparation (control), wild-type ADAMTS-2 (wtTS2) or catalytically inactive ADAMTS-2 (mTS-
2). Asterisks indicate the most abundant form of ADAMTS-2 (* for wild-type ADAMTS-2 and ** for catalytically 
inactive ADAMTS-2). b HUVEC or HMEC were seeded on gelatin coats for 3 h in serum-free EBM and cultured 
for 16 h in medium supplemented with the control preparation (control), the wild-type ADAMTS-2 (wtTS-2) or 
catalytically inactive ADAMTS-2 (mTS-2), both at 5 "g/ml. Bar 100 "m. c The proliferation rate of HUVEC was 
measured by 3H-thymidine uptake in cultures (n = 6) in the presence of wtTS2 (dark grey bar), of mTS2 (light 
grey bar) both at 5 "g/ml, or of the same amount of control preparation (0 "g/ml, black bar). The results are 
representative of three separate experiments (***p < 0.001). d HMEC were incubated for 6 h at 8°C in serum-
free medium supplemented with wild-type ADAMTS-2 (a) or catalytically inactive ADAMTS-2 (b) both at 2 
"g/ml and immuno-stained for the presence of ADAMTS-2 immobilized at the cell surface. Bar 50 "m 
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Fig. 12 Effect of different recombinant forms of ADAMTS-2 on tumor growth. The experimental procedure was 
as detailed in Fig. 9 (n = 4). A schematic domains organization of the four different recombinant ADAMTS-2 
expressed by cells forming the tumors is provided at the top of each corresponding graphics. Tumor volume was 
measured every 3-4 days. Control tumors are represented by bold plain black lines while tumors formed by the 
different forms of ADAMTS-2 are illustrated by dotted grey lines (a wild-type ADAMTS-2; b mutated 
catalytically inactive ADAMTS-2; c ADAMTS-2 lacking the central domains including the metalloproteinase 
domain; d ADAMTS-2 lacking the C-terminal domains). Insets in a-d illustrate the mean tumor mass after 
dissection, e The proliferation rate of control HEK-293 EBNA cells (bold dark line) or of HEK-293 EBNA cells 
expressing the different forms of ADAMTS-2 (dotted grey lines) was evaluated by DNA quantification 
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Discussion 
Angiogenesis plays a critical role in cancer progression and metastasis [32]. Tumor growth and dissemination 
have been shown to be dependent on neovascularization, explaining why inhibition of tumoral angiogenesis by 
selectively inhibiting growth, survival, and migration of endothelial cells is still perceived today as an attractive 
tool for controlling cancer progression [3, 33, 34]. The potential anti-angiogenic properties of ADAMTS-2 were 
hypothesized on the basis of similarities between sequences and domains involved in the inhibitory activity of 
thrombospondin 1 and 2 and ADAMTS-1 and -8. Antiproliferative properties of recombinant ADAMTS-2 was 
first investigated on endothelial cell cultures in monolayer. ADAMTS-2 reproducibly inhibited the proliferation 
of microvascular and umbilical vein endothelial cells, with a maximal repression observed between 1 and 5 
#g/ml. These concentrations (~5-40 nM) are in the same range as those reported for thrombospondin 2 [35] and 
ADAMTS-1 and -8 [14]. At similar concentrations, the proliferation of human fibroblasts and smooth-muscle 
cells was not altered, demonstrating the specificity towards endothelial cells. As opposed to ADAMTS-1 [13], 
the anti-proliferative effect of ADAMTS-2 on endothelial cells does not seem to result from interactions with a 
growth factor or interference with a growth factor pathway as the relative repression exerted by ADAMTS-2 was 
similar in the absence or presence of VEGF and/or FGF-2. 
Morphological changes induced by ADAMTS-2 were evaluated using cells cultured on various extracellular 
matrices in the absence of any mitogenic stimulus. The alterations, observed within the first hour of contact and 
worsening with time, consisted of a progressive detachment and retraction of the cellular body with the 
persistence of thin extensions resembling filipodia. Actin cytoskeleton and focal adhesions were also rapidly and 
profoundly disorganized. The observed changes were similar in endothelial cells spread onto various 
extracellular matrix proteins, suggesting that either most of the integrins are targeted by ADAMTS-2 or that they 
are not involved in the process. Analysis of the entire process by videomicroscopy clearly confirmed the 
progressive loss of contact between endothelial cells and the matrix, further resulting in rapid random cell 
movements, formation of cell clusters, and ultimately cell death. The presence of numerous blebbing cells and 
the results of FACS analysis were both indicative of a pro-apoptotic activity of ADAMTS-2, most probably by 
anoikis. 
The rapidity of the effect of ADAMTS-2 strongly suggested the existence of early alterations of intracellular 
regulatory pathways. Addition of ADAMTS-2 to endothelial cells indeed resulted in a reduced phosphorylation 
of MLC within 10 min, a feature that would explain the fast and pronounced disorganization of the actin 
cytoskeleton and rounding of the cells. The decreased phosphorylation of FAK observed at later time points in 
ADAMTS-2 treated cells might also result from such cytoskeleton disruption. In astrocytes, the RhoA/ROCK1/ 
MLC pathway regulates the process of actin reorganization, cell retraction and rounding, and anoikis [36]. In our 
cells, inhibition of ROCK by Y27632 strongly decreased the level of phosphorylated MLC, demonstrating the 
efficiency of this inhibitor, but did not mimic (neither prevent) the effect of ADAMTS-2. This indicated that this 
specific pathway was not essential in our model. Similarly, Rac1-, Cdc42-, and p38-mediated pathways did not 
seem to be involved since the phosphorylation of PAK and p38 was not modified. By contrast, binding of 
ADAMTS-2 to the endothelial cell surface rapidly repressed the phosphorylation of Erk1/2, an ubiquitous 
intracellular mediator implicated in various pathways regulating a large array of cell functions. A similar effect 
on Erk1/2 activity was recently observed for ADAMTS-12 using Madin-Darby Canine Kidney (MDCK) cells 
[37]. This inhibition was already evident after 10 min, before any visible morphological alterations, suggesting 
that modification of the Erk1/2 signaling is perhaps one of the causes (not consequences) of the disorganization 
of actin cytoskeleton. This is also in agreement with our data regarding fibroblasts. Although these cells bind a 
large amount of ADAMTS-2 at their surface, they are not affected in terms of morphology and survival, which 
correlates with a different pattern of response in terms of Erk1/2 phosphorylation. 
The rapid and strong response of endothelial cells to ADAMTS-2 suggested a direct interaction between cells 
and the enzyme. Such interaction was evidenced after incubation of endothelial cells with recombinant 
ADAMTS-2 and visualization of cell surface-bound enzyme. Interestingly, fibroblasts were also strongly 
labeled, although they were not affected by ADAMTS-2 in terms of survival, proliferation, and morphology. 
ADAMTS-2 binding to the endothelial cell surface is heparin-, heparinase III-, and chlorate-sensitive, suggesting 
that it involves, directly or indirectly, a heparan sulfate proteoglycan (HSPG). However, although efficient in 
terms of preventing ADAMTS-2 binding, heparinase III treatment did not significantly prevent the pro-apoptotic 
effect of ADAMTS-2 on endothelial cells. Although it could not be completely ruled out that it is related to an 
incomplete cleavage of HS-side chains, a more likely explanation would be that HSPG are not necessary to 
mediate the signaling induced by ADAMTS-2. There are indeed many examples showing that HSPG can bind 
growth factors (FGF-2, VEGF, ...), potentiating their biological activity by increasing their local concentration 
and availability near their specific receptors, but are not strictly required for the transmission of the growth factor 
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signal [38, 39]. Affinity chromatography using ADAMTS-2 as a bait and co-localization studies identified 
nucleolin as a potential membrane receptor for ADAMTS-2. Nucleolin was initially described as a nucleolar 
protein participating in the transcriptional control of ribosomal RNA genes, in ribosomes maturation and 
assembly, and in the nucleocytoplasmic transport of ribosomal components [40, 41]. It has also been shown that 
nucleolin can translocate to the plasma membrane in some specific cell types such as endothelial cells and many 
transformed cells [42]. When present at the cell surface, it has been shown that nucleolin can interact with Erb B 
receptors or serves as a receptor for L-selectin, midkine and, most interestingly, endostatin [43], a potent anti-
angiogenic fragment of collagen XVIII. The implication of nucleolin in the control of angiogenesis was 
strengthened by recent publications showing that an antibody targeting the acidic domain of nucleolin caused 
apoptosis of cultured endothelial cells and was anti-angiogenic in vitro and in vivo [44]. A direct interaction 
between this acidic domain and ADAMTS-2 would not be surprising considering that ADAMTS-2 has affinity 
for the negatively charged heparin and HSPG and that the heparin-binding domain of endostatin is required for 
its efficient binding on the acidic domain of nucleolin. Moreover, a specific antagonist of cell-surface nucleolin 
reduces the phosphorylation of Erk1/2 within a few minutes and suppresses tumor growth and angiogenesis [45], 
two features also observed here for ADAMTS-2. The hypothesis that nucleolin is a receptor mediating the 
proapoptotic effect of ADAMTS-2 may seemed challenged by the observation that HEK 293-EBNA cells are not 
affected by ADAMTS-2 although they express nucleolin at their surface (not shown). Similar data have been 
obtained with endostatin, which induces apoptosis in endothelial cells and some transformed cells while other 
cell types, although expressing nucleolin, are not altered [43]. Cell-specific intracellular pathways or the 
requirement of specific membrane co-receptors may explain this apparent discrepancy. Due to its vital 
importance for many cellular processes, we consider that repression of nucleolin by RNAi would not be 
appropriate for evaluating its implication as a "receptor" mediating apoptosis. Moreover, the amount of cell 
surface nucleolin may not be directly correlated to its overall abundance. Specific targeting of membrane 
nucleolin would be more suitable but is currently impossible because of the unavailability of blocking 
antibodies. 
The antiangiogenic properties of ADAMTS-2 were also assessed in vivo. In a choroidal neovascularization 
model [46], a reproducible and significant increase of neovascularization was observed in ADAMTS-2-/- mice as 
compared to wild-type animals, supporting an antiangiogenic function for ADAMTS-2 in vivo. In a second 
model, HEK 293-EBNA cells were grafted subcutaneously to induce formation of tumors in nude mice [47]. The 
parental cells formed rapidly growing tumors characterized by the development of a dense network of functional 
blood vessels. When cells expressing wild-type ADAMTS-2 were used, tumor growth was drastically reduced, 
the small cell plugs were whiter and many necrotic areas were detected. Since control cells and cells expressing 
ADAMTS-2 grow at a similar rate, all these observations are most probably related to the absence of an efficient 
blood supply since only small and collapsed vessels are present in these tumors, again illustrating the anti-
angiogenic properties of ADAMTS-2. 
The same models were used to identify the specific domain(s) of ADAMTS-2 that is responsible for its 
antiangiogenic effects. Three different types of mutated ADAMTS-2 were produced. The catalytically inactive 
ADAMTS-2, resulting from a point mutation in the metalloproteinase domain, could be purified with the same 
efficiency as the wild-type enzyme. However, its molecular size is different since a functional catalytic pocket is 
required for the autocatalytic processing of PNP terminal domain [19]. As an additional difference, it was found 
that this incompletely processed form tends to form aggregates and to precipitate when purified and concentrated 
in physiological saline conditions (D. Hulmes, unpublished data). The two other recombinant enzymes, lacking 
either the central or the C-terminal domains, could not be sufficiently purified using procedures developed for 
the wild-type ADAMTS-2, most probably due to the absence of specific sequences and glycosylation required 
for affinity chromatography. Therefore only the recombinant ADAMTS-2 lacking metalloproteinase activity was 
evaluated in vitro for its effects on angiogenesis. It binds on endothelial cells and alters their morphology and 
proliferation rate, although to a lesser extent than the wild-type enzyme. It clearly demonstrates that the effect of 
ADAMTS-2 on endothelial cells does not directly involve its catalytic activity. It also shows that the persistence 
of the PNP domain has functional consequences in in vitro model of angiogenesis possibly by modifying 
availability and/or exposure of specific domains at the surface of the molecule or by reducing the solubility and 
therefore the specific concentration of ADAMTS-2. As the model of tumor growth does not require a 
purification process, it was used to evaluate the effect of the three mutant forms of ADAMTS-2 (Fig. 12). The 
catalytically inactive ADAMTS-2 efficiently prevented tumor growth, in agreement with the in vitro data. The 
two other mutated variants lacking specific domain were also active in restricting tumor growth. This would 
indicate that a common domain is responsible for the effect. The pro-domain is certainly not implicated since it 
is cleaved during secretion and is not present in purified enzyme used in vitro [19]. This would indicate that the 
short aminoterminal extremity of the metalloproteinase domain and/or the 132 amino acid-long spacer domain, 
which are common in all these constructs, are possibly involved. The spacer domain of ADAMTS-4 or 
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ADAMTS-5 has been shown to modulate the proteolytic activity of the enzyme [48] but a structural function 
unrelated to the enzymatic activity has never been described so far. As an alternative hypothesis, antiangiogenic 
activity could be operated by two different TSR1 domains: the first, which is the only one present in the 
ADAMTS-2 lacking the C-terminal domain, and any of the three TSR1 that are still conserved in the ADAMTS-
2 deprived of its central domain. The initial observations of the antiangiogenic potential of TSR1 domains were 
made during the study of thrombospondins 1 and 2 [8]. Various other TSR1 domains from different types of 
proteins, including ADAMTS-4, -16 and -18, have been previously tested [49]. Some of them significantly 
reduced (10-50%) endothelial cell proliferation but only at much higher concentration (500 nM-20 #M) as 
compared to the active concentration of ADAMTS-2 used here (2 #g/ml; around 16 nM). It has also been shown 
that the first (but not the second) TSR1 of ADAMTS-5 inhibited proliferation and increased apoptosis of 
endothelial cells at concentration ranging from 100 to 1,000 nM. Concerning ADAMTS-1 its antiangiogenic 
effect largely results from its specific interactions with VEGF165 [13] or depends on its catalytic activity [16], 
two mechanisms that are not implicated for ADAMTS-2. These data show that these closely related enzymes can 
affect angiogenesis with different efficiency and through different pathways. They also illustrate the significance 
and the complexity of their functions and, therefore, demonstrate the need of an extensive characterization of 
both their active domain(s) and their specific receptor(s). 
Acknowledgments  
This work was supported by grants from the Belgian Fonds de la Recherche Scientifique Médicale (Grant nos. 
3.4362.03 and 3.4387.05), the Belgian Fonds National de la Recherche Scientifique, the "Foundation against 
Cancer", the "Fondation Léon Fredericq" (University of Liège), the "Centre Anticancéreux près l'Université de 
Liège" and the "Région Wallonne" (NeoAngio, grant no. 616476). We thank the "Proteomic" (M.-A. Meuwis) 
and "Imaging and Flow cytometry" (Sandra Ormenese) platforms of GIGA-R (University of Liège) and Dr. 
Prockop (Texas A&M Health Science Center, USA) for the kind gift of ADAMTS-2-/- mice. 
References 
1.  Bix G, Iozzo RV (2005) Matrix revolutions: "tails" of basement-membrane components with angiostatic functions. Trends Cell Biol 
15:52-60 
2.  Sottile J (2004) Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 1654:13-22 
3.  Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409-416 
4.  Armstrong LC, Bornstein P (2003) Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63-71 
5.  Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML (2006) ADAMTS1 mediates the release of antiangiogenic 
polypeptides from TSP1 and 2. EMBO J 25:5270-5283 
6.  Adams JC (2001) Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17:25-51 
7.  Febbraio M, Hajjar DP, Silverstein RL (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, 
inflammation, and lipid metabolism. J Clin Invest 108:785-791 
8.  Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N (1993) Peptides derived from two separate domains of the matrix 
protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511 
9.  Grant MA, Kalluri R (2005) Structural basis for the functions of endogenous angiogenesis inhibitors. Cold Spring Harb Symp Quant Biol 
70:399-410 
10.  O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a 
novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328 
11.  Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV (2005) Angiostatin's molecular mechanism: aspects of specificity and regulation 
elucidated. J Cell Biochem 96:242-261 
12.  Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkila P, Rehn M, Sorsa T, Salo T, Pihlajaniemi T (2005) Generation of 
biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 307:292-304 
13.  Luque A, Carpizo DR, Iruela-Arispe ML (2003) ADAMTS1/ METH1 inhibits endothelial cell proliferation by direct binding and 
sequestration of VEGF165. J Biol Chem 278:23656-23665 
 
Published in : Cellular & Molecular Life Sciences (2010) 
Status : Postprint (Author’s version) 
 
14.  Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M,  Iruela-Arispe ML  (1999)  METH-1,  a human ortholog of 
ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274:23349-23357 
15.  Iruela-Arispe ML, Luque A, Lee N (2004) Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 36:1070-1078 
16.  Iruela-Arispe ML, Carpizo D, Luque A (2003) ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann NY Acad Sci 
995:183-190 
17.  Colige A, Beschin A, Samyn B, Goebels Y, Van Beeumen J, Nusgens BV, Lapiere CM (1995) Characterization and partial amino acid 
sequencing of a 107-kDa procollagen I N-proteinase purified by affinity chromatography on immobilized type XIV collagen. J Biol Chem 
270:16724-16730 
18.  Colige A, Li SW, Sieron AL, Nusgens BV, Prockop DJ, Lapiere CM (1997) cDNA cloning and expression of bovine procollagen I N-
proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc Natl 
Acad Sci USA 94:2374-2379 
19.  Colige A, Ruggiero F, Vandenberghe I, Dubail J, Kesteloot F, Van Beeumen J, Beschin A, Brys L, Lapiere CM, Nusgens B (2005) 
Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the am-inopropeptide of fibrillar 
procollagens types I-III and V. J Biol Chem 280:34397-34408 
20.  Colige A, Sieron AL, Li SW, Schwarze U, Petty E, Wertelecki W, Wilcox W, Krakow D, Cohn DH, Reardon W, Byers PH, Lapiere 
CM, Prockop DJ, Nusgens BV (1999) Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in 
the procollagen I N-proteinase gene. Am J Hum Genet 65:308-317 
21.  Wang WM, Lee S, Steiglitz BM, Scott IC, Lebares CC, Allen ML, Brenner MC, Takahara K, Greenspan DS (2003) Transforming 
growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J Biol Chem 278:19549-19557 
22.  Colige A, Nuytinck L, Hausser I, van Essen AJ, Thiry M, Herens C, Ades LC, Malfait F, Paepe AD, Franck P, Wolff G, Oosterwijk JC, 
Smitt JH, Lapiere CM, Nusgens BV (2004) Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome 
(Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol 123:656-663 
23.  Li SW, Arita M, Fertala A, Bao Y, Kopen GC, Langsjo TK, Hyttinen MM, Helminen HJ, Prockop DJ (2001) Transgenic mice with 
inactive alleles for procollagen N-proteinase (ADAMTS-2) develop fragile skin and male sterility. Biochem J 355:271-278 
24.  Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification 
by morphologic and immunologic criteria. J Clin Invest 52:2745-2756 
25.  Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ (1992) HMEC-1: establishment of an immortalized 
human microvascular endothelial cell line. J Invest Dermatol 99:683-690 
26.  Colige AC, Lambert CA, Nusgens BV, Lapiere CM (1992) Effect of cell-cell and cell-matrix interactions on the response of fibroblasts 
to epidermal growth factor in vitro. Expression of collagen type I, collagenase, stromelysin and tissue inhibitor of metalloproteinases. 
Biochem J 285(Pt 1):215-221 
27.  Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW (2005) Platelet-derived growth factor-BB-induced human smooth 
muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 96:172-179 
28.  Labarca C, Paigen K (1980) A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344-352 
29.  Deroanne CF, Colige AC, Nusgens BV, Lapiere CM (1996) Modulation of expression and assembly of vinculin during in vitro fibrillar 
collagen-induced angiogenesis and its reversal. Exp Cell Res 224:215-223 
30.  Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V 
(2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427-436 
31.  Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA (1998) Targeted disruption 
of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153:1641-1646 
32.  Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 
33.  Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. 
Bioessays 13:31-36 
34.  Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049 
35.  Noh YH, Matsuda K, Hong YK, Kunstfeld R, Riccardi L, Koch M, Oura H, Dadras SS, Streit M, Detmar M (2003) An N-terminal 80-
kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in 
vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121:1536-1543 
Published in : Cellular & Molecular Life Sciences (2010) 
Status : Postprint (Author’s version) 
 
36.  Minambres R, Guasch RM, Perez-Arago A, Guerri C (2006) The RhoA/ROCK-I/MLC pathway is involved in the ethanol-induced 
apoptosis by anoikis in astrocytes. J Cell Sci 119:271-282 
37.  Llamazares M, Obaya AJ, Moncada-Pazos A, Heljasvaara R, Espada J, Lopez-Otin C, Cal S (2007) The ADAMTS12 metalloproteinase 
exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 120:3544-3552 
38.  Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K (2010) Structure-function analysis of VEGF receptor activation and the role of 
coreceptors in angiogenic signaling. Biochim Biophys Acta 1804:567-580 
39.  Kinsella MG, Irvin C, Reidy MA, Wight TN (2004) Removal of heparan   sulfate   by   heparinase   treatment   inhibits   FGF-2-
dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175:51-57 
40.  Di Segni A, Farin K, Pinkas-Kramarski R (2008) Identification of nucleolin as new ErbB receptors-interacting protein. PLoS One 
3:e2310 
41.  Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 
13:1911-1922 
42.  Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E (2003) Nucleolin expressed at the cell surface is a marker of 
endothelial cells in angiogenic blood vessels. J Cell Biol 163:871-878 
43.  Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, Luo Y (2007) Nucleolin is a receptor that mediates antiangiogenic and antitu-mor 
activity of endostatin. Blood 110:2899-2906 
44.  Fogal V, Sugahara KN, Ruoslahti E, Christian S (2009) Cell surface nucleolin antagonist causes endothelial cell apoptosis and 
normalization of tumor vasculature. Angiogenesis 12:91-100 
45.  Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG 
(2008) Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 3:e2518 
46.  Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell HW, Foidart JM, Noel A, Rakic JM 
(2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290-2292 
47.  Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y, Noel A, Voo S, Waltenberger J, Lapiere CM, Nusgens BV, 
Lambert CA (2007) Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic 
agents. J Cell Biol 179:1261-1273 
48.  Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H (2008) Functional differences of the catalytic and non-catalytic domains in 
human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 283:6706-6716 
49.  Karagiannis ED, Popel AS (2007) Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res 
Commun 359:63-69 
